Pre-made Fresolimumab biosimilar ( Whole mAb, anti-TGFB therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-223
Anti-TGFB therapeutic antibody (Pre-made Fresolimumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Fresolimumab (GC1008) is a human monoclonal antibody and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer (kidney cancer and melanoma).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TGFB therapeutic antibody (Pre-made Fresolimumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EF:GK:HL:JI/3eo1:BA:ED:KJ:HG|
|95-98% SI Structure||None|
|Companies||Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme|
|Conditions Discontinued||Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta|
|Development Tech||CAT Phage Display|